This medical affairs educational lecture will overview key clinical and translational applications enabled by sequencing technology. Clinicians, medical staff, clinical and translational researchers, genetic counsellors, and others seeking education in this area are encouraged to attend.

- Overview of recent advances in testing technologies that are allowing interrogation of cancer genetics on an unprecedented scale
- Overview of lessons learned in the past few decades about the genomic basis of cancer

-Complexity of genomic lesions in cancer
-Tumor heterogeneity
-Exceptional responders

- Potential clinical applications of genomic testing in cancer

-Targeted treatments
Comprehensive genomic testing (companion diagnostics vs companion therapeutics)
-Genomic testing beyond treatment selection applications
-Circulating nucleic acids

Presenter: Daniel S. Grosu, MD, MBA
VP, Clinical Development & Medical Affairs Illumina, San Diego, CA, USA
Dr. Daniel Grosu joined Illumina in 2011 as the Company’s first Chief Medical Officer and currently serves as Vice President of Clinical Development and Medical Affairs. He led the team that carried out the clinical trials supporting the validation of the MiSeqDx, the first NGS platform to receive FDA clearance in the USA and CE Marking in Europe. Dr. Grosu has had a longstanding interest in innovative diagnostic technologies, spanning previous assignments with Siemens Medical Solutions, Bayer HealthCare Pharmaceuticals, and Johnson & Johnson. He holds an MD (with Distinction in Research) from Saint Louis University School of Medicine, and an MBA from the University of Oxford.

Please contact Dr Bruce Wyse, UQ Diamantina Institute, or [email protected] with any questions